We are a clinical-stage biotechnology company developing best-in-class bromodomain and extra-terminal inhibitors (BETi) for the treatment of multiple cancers and other disorders with significant unmet medical need. Our goal is to be a leading oncology company in the field of epigenetics, translating bromodomain biology into impactful, targeted therapeutics for the benefit of patients.

Learn More

About Zenith Epigenetics

Zenith Epigenetics’ experienced research team has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET inhibitors. Our experienced management team and world-leading clinical collaborators are developing BETi combination therapies for multiple oncology indications. With a strong emphasis on translational medicine – for selecting patients that will benefit most from the therapy – Zenith is a leader in innovative clinical development of epigenetic combination therapies.

Our lead BETi, ZEN-3694, is in Phase 2 clinical development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer.



Zenith Capital Corp. Annual and Special Meeting of Shareholders

The Zenith Capital Corp. Annual and Special Meeting of Shareholders was held on December 22, 2020. The corporate presentation can be accessed HERE.

Add This to my Calendar

Epigenetic Therapeutic Targets Virtual Summit

On July 28, 2020, Zenith participated in the Epigenetic Therapeutic Targets Virtual Summit, with an oral presentation by Dr. Eric Campeau, titled: "Design of combination strategies and identification of biomarkers associated with clinical response to ZEN-3694 in combination with enzalutamide in mCRPC." The presentation PDF can be accessed HERE.

Add This to my Calendar